Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus
Journal of Clinical Microbiology · 24.10.2023 · 61 (10)
DOI: 10.1128/jcm.00429-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 24.10.2023. Verfasst von Nicholas T Streck und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Mayo Clinic , Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality among immunocompromised hosts, including transplant recipients. Antiviral prophylaxis or treatment is used to reduce the incidence of CMV disease in this patient population; however, there is concern about increasing antiviral resistance. Detection of antiviral resistance in CMV was traditionally accomplished using Sanger sequencing of UL54 and UL97 genes, in which specific mutations may result in reduced antiviral activity. In this study, a novel next-generation sequencing (NGS) method was developed and validated to detect mutations in UL54 / UL97 associated with antiviral resistance. Plasma samples ( n = 27) submitted for antiviral resistance testing by Sanger sequencing were also analyzed using the NGS method. When compared to Sanger sequencing, the NGS assay demonstrated 100% (27/27) overall agreement for determining antiviral resistance/susceptibility and 88% (22/25) agreement at the level of resistance-associated mutations. The limit of detection of the NGS method was determined to be 500 IU/mL, and the lower threshold for detecting mutations associated with resistance was established at 15%. The NGS assay represents a novel laboratory tool that assists healthcare providers in treating patients who are infected with CMV harboring resistance-associated mutations and who may benefit from tailored antiviral therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Microbiology, Mayo Clinic , Rochester, Minnesota, USA.
- Division of Laboratory Genetics and Genomics, Mayo Clinic , Rochester, Minnesota, USA.
- Division of Biomedical Statistics and Informatics, Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, Minnesota, USA.
- Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic , Rochester, Minnesota, USA.
- ABL Diagnostics , Woippy, France.
- Health Partners Medical Laboratory and Pathology Services , Bloomington, Minnesota, USA.
ORCID-Profile: Nicholas T Streck, Matthew J Binnicker
Zitieren
APA
Streck, N. T., Espy, M. J., Ferber, M. J., Klee, E. W., Razonable, R. R., Gonzalez, D., Sayada, C., Heaton, P. R., Chou, S., & Binnicker, M. J. (2023). Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus. Journal of Clinical Microbiology, 61(10). https://doi.org/10.1128/jcm.00429-23
Vancouver
Streck NT, Espy MJ, Ferber MJ, Klee EW, Razonable RR, Gonzalez D, et al. Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus. Journal of Clinical Microbiology. 2023;61(10). doi:10.1128/jcm.00429-23
BibTeX
@article{Streck2023,
author = {Streck, Nicholas T and Espy, Mark J and Ferber, Matthew J and Klee, Eric W and Razonable, Raymund R and Gonzalez, Dimitri and Sayada, Chalom and Heaton, Phillip R and Chou, Sunwen and Binnicker, Matthew J},
title = {Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus},
journal = {Journal of Clinical Microbiology},
year = {2023},
volume = {61},
number = {10},
doi = {10.1128/jcm.00429-23}
}
EUVIMED